How well do boosters work? Depends on your genes

Computer modeling links a person's genes to whether producing more antibodies will help them fight off the disease.

10:39 AM

Author | Jim Lynch

woman scientist laptop lab dark
Kelly Arnold, senior author of a paper that uses a computational model to understand how genetics may influence an individual’s immune response to vaccine boosting. Photo: Brenda Ahearn/Michigan Engineering

Genetics play an important role in how our bodies respond to vaccines and booster shots, suggesting that certain protective responses elicited by vaccination  could be more effective with personalization, according to a new study led by University of Michigan researchers.

The team also identified a particular form of an antibody-related gene that predicts, at a population level, whether boosting to produce more antibodies will be effective for increasing innate immune responses.

"What's most interesting with this work is the concept of personalized variability and understanding direct links between vaccine responses and different genes people have," said Kelly Arnold, U-M assistant professor of biomedical engineering and senior author of the paper in Frontiers in Immunology.

The study explored how people may respond differently to conventional boosting, which reexposes the immune system to the virus (or some portion of it) to increase antibody concentration.

However, in some people, the increase in antibody concentration may not matter as much because their genes encode for immune receptors that aren't as good at sticking to the antibodies—they're said to have a lower affinity. 

As a result, a person can have a respectable antibody count and still have a poor immune response. So one theoretical alternate immune-boosting route could be to design vaccines that tweak the structure of the antibodies—making those antibodies more likely to stick to a person's immune cell receptors.

"Depending on your genetic background, we've found that vaccine boosting may be more or less effective in activating certain innate immune functions," Arnold said. "And in some people, where boosting the concentrations of antibodies was ineffective, being able to change the affinity of antibodies could be the more successful route. Though this is still a theoretical concept and not yet possible in practice."

Arnold's team, working with partners in Australia, Thailand and the U.S., created a computer model to determine how different genetic factors influence innate immune responses induced by vaccine boosting. It uses data and plasma samples obtained by the University of Melbourne from the only moderately protective HIV vaccine trial to date. 

The plasma samples from trial participants—basically blood samples minus the red blood cells—showed the amount and type of antibodies produced after vaccination. 

"In a mixed population of people, we've also shown how one specific genotype would drive whether that population was responsive to changes in antibody concentrations expected from traditional boosting," Arnold said. 

Modeling showed that, in a gene that encodes for a specific type of antibody (IgG1), different variations can predict how effective boosting to increase antibody levels will be in a given population. Some populations in the HIV trial showed that increasing antibody levels resulted in no change in the innate immune functions that were being evaluated. 

"What that tells us is that in populations with certain genetic variations, traditional boosting methods to increase antibody concentrations may not be as effective at improving innate immune functions," Arnold said.

Adjuvants are the vaccine ingredients designed to improve the body's immune response.

Last year, Arnold's team utilized data from the same trial to highlight why certain vaccines influence people differently. In the future, both studies could lead to new design principles for vaccines that take an individual's personalized characteristics into account.

The research was funded by the Australia National Health & Medical Research Center, the American Foundation for AISD Research Mathilde Krim Fellowship and the University of Michigan.

The collaboration included the University of Melbourne, Monash University and the Burnet Institute in Australia; Mahidol University, the Ministry of Public Health and the Armed Forces Research Institute of Medical Science in Thailand; and the Ragon Institute of Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology in the United States.

This article was originally published by Engineering Research News.


More Articles About: Body Work Covid-19 COVID-19 Vaccine Community Health Genetics infectious disease
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories orange cells floating squiggly lines coming out of it with blurred blue and purple colors
Health Lab
Clinically deployed AI guidance for preventing C. difficile spread
AI guidance for clinicians aimed at reducing the spread of C.diff was deployed for the first time in a hospital setting, according to a University of Michigan-led study.
father and son standing together and book cover
Health Lab
One doctor’s American dream: to stop hate
Asian-American history is American history. William D. Chey shares his immigrant father’s legacy, his own experience and calls on youth to practice the values of diversity, equity and inclusion throughout their lives.
mom with sick child on phone checking tempature
Health Lab
Drug that treats flu shows additional benefit of protecting close contacts from infection
One dose of the antiviral baloxavir marboxil lowers the chance of transmitting the influenza virus to family members by about 30%, according to research.
close up on person looking at bottle of pills with water in background
Health Lab
More young adults than ever take HIV-prevention medication, but gaps remain
The use of PrEP (treatment that can protect someone from acquiring HIV) has risen in young adults but gaps still remain, a study finds.
lungs beating pink and orange and yellow and white circles floating around
Health Lab
Protein found in rheumatic diseases causes inflammation in COVID-19 patients
Research on the inflammatory mediator called sCD13 has identified this molecule and its receptors as new targets for treatment of autoimmune rheumatic diseases. The data suggests that sCD13 may also be of great importance in severe complications of COVID-19.
Smiling black and white photo of Phil Jenkins seated at his desk. He is dressed up in a button-up shirt and tie.
Philanthropy News
$3M Jenkins Foundation Gift Ensures Future of Depression Outreach Programs
Jenkins Foundation makes $3 million gift to the Kenneth and Frances Eisenberg and Family Depression Center to sustain outreach and community education programs.